MiR-200c and HuR in ovarian cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Prislei, Silvia ^a   Martinelli, Enrica ^a   Mariani, Marisa ^a,b   Raspaglio, Giuseppina ^a   Sieber, Steven ^b   Ferrandina, Gabriella ^c   Shahabi, Shohreh ^b   Scambia, Giovanni ^a,c   Ferlini, Cristiano ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b DANBURY HOSPITAL   (United States)

^c Jean Paul IInd Research Foundation   (Italy)

Author keywords

Class III beta tubulin; HuR; MiR 200c; Ovarian cancer; Predictive biomarkers

Indexed keywords

BETA TUBULIN; CISPLATIN; HUR PROTEIN; MESSENGER RNA; MICRORNA 200C; PACLITAXEL; PROTEIN TUBB3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; NANOFLUIDICS; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; OVARY CANCER; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN STABILITY; RNA TRANSLATION;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CISPLATIN; CYTOPLASM; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NANOTECHNOLOGY; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84873422357     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-72     Document Type: Article

References (28)

1. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006, 98(22):1655-1663. 10.1093/jnci/djj443, 17105988.
2. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10(10):704-714. 10.1038/nrg2634, 3467096, 19763153.
3. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67(18):8699-8707. 10.1158/0008-5472.CAN-07-1936, 17875710.
4. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14(9):2690-2695. 10.1158/1078-0432.CCR-07-1731, 18451233.
5. Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol 2010, 42(1):25-30. 10.1016/j.biocel.2009.10.016, 19854294.
6. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009, 114(2):253-259.
7. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009, 114(3):457-464. 10.1016/j.ygyno.2009.05.022, 19501389.
8. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011, 18(1):85-95.
9. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011, 12(3):273-285. 10.1016/S1470-2045(11)70012-2, 21345725.
10. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010, 42(8):1282-1290. 10.1016/j.biocel.2010.01.014, 20083225.
11. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?. EMBO Rep 2010, 11(9):670-677. 10.1038/embor.2010.117, 2933868, 20706219.
12. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8(5):1055-1066. 10.1158/1535-7163.MCT-08-1046, 19435871.
13. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006, 12(9):2774-2779. 10.1158/1078-0432.CCR-05-2715, 16675570.
14. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol 2010, 2010:821717. 2798671, 20049172.
15. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, et al. Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel. Mol Cancer Ther 2012, 11(12):2556-2565. 10.1158/1535-7163.MCT-12-0463, 23074172.
16. Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S, Scambia G, Ferlini C. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010, 70(14):5891-5900. 10.1158/0008-5472.CAN-09-4656, 20587520.
17. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008, 409(1-2):100-108.
18. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009, 107(6):1053-1062. 10.1002/jcb.22214, 19479945.
19. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 2010, 1(2):214-229.
20. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011, 11(9):644-656. 10.1038/nrc3107, 21822212.
21. Lee S, Vasudevan S. Post-transcriptional Stimulation of Gene Expression by MicroRNAs. Adv Exp Med Biol 2013, 768:97-126. 10.1007/978-1-4614-5107-5_7, 23224967.
22. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 2005, 65(6):2397-2405. 10.1158/0008-5472.CAN-04-3065, 15781655.
23. Vasudevan S, Steitz JA. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 2007, 128(6):1105-1118. 10.1016/j.cell.2007.01.038, 3430382, 17382880.
24. Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C. Molecular mechanisms of patupilone resistance. Cancer Res 2008, 68(24):10197-10204. 10.1158/0008-5472.CAN-08-2091, 19074887.
25. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2011, 227:1034-1041.
26. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007, 67(19):9356-9363. 10.1158/0008-5472.CAN-07-0509, 17909044.
27. Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, Ascano M, Tuschl T, Ohler U, Keene JD. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell 2011, 43(3):327-339. 10.1016/j.molcel.2011.06.007, 3220597, 21723170.
28. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11(9):597-610.